ACUTE\u00a0respiratory distress syndrome subtypes can now be rapidly\u00a0identified\u00a0at the bedside, with new prospective data confirming that distinct inflammatory profiles are linked to significantly different survival outcomes.\u00a0<\/p>\n
Acute respiratory distress syndrome is a severe and often fatal condition in intensive care, with no effective pharmacological treatments currently available. Efforts to improve outcomes have increasingly focused on understanding its biological heterogeneity and\u00a0identifying\u00a0patient subgroups that may respond differently to therapy.\u00a0<\/p>\n
Acute Respiratory Distress Syndrome Subtypes Identified Rapidly\u00a0<\/p>\n
In this large multicentre study, researchers prospectively enrolled patients with acute respiratory distress syndrome or acute\u00a0hypoxaemic\u00a0respiratory failure in intensive care units. Using a near-patient immunoassay, they measured key inflammatory biomarkers, including\u00a0IL-6 and\u00a0TNF\u00a0receptor-1, alongside blood bicarbonate levels.\u00a0<\/p>\n
These measurements enabled classification into two acute respiratory distress syndrome subtypes,\u00a0hyperinflammatory and\u00a0hypoinflammatory,\u00a0within approximately one hour,\u00a0demonstrating\u00a0feasibility for real-time clinical use.\u00a0<\/p>\n
Higher Mortality in Hyperinflammatory Subtype\u00a0<\/p>\n
Among patients successfully\u00a0subphenotyped, 18% were classified as hyperinflammatory. This group experienced markedly worse outcomes, with a 60-day mortality rate of 51%, compared with 28% in the\u00a0hypoinflammatory\u00a0group.\u00a0<\/p>\n
Even after adjustment for confounding factors, the hyperinflammatory subtype remained strongly associated with increased mortality risk, reinforcing the clinical significance of these biological differences.\u00a0<\/p>\n
From Retrospective Evidence to Real-Time Practice\u00a0<\/p>\n
Previous\u00a0research had consistently\u00a0identified\u00a0acute respiratory distress syndrome subtypes and linked them to prognosis and treatment response. However, these findings were based on retrospective analyses, limiting their immediate clinical applicability.\u00a0<\/p>\n
This study provides the first prospective evidence that\u00a0subphenotypes\u00a0can be reliably\u00a0identified\u00a0in real time at the bedside. The use of a near-patient testing platform across multiple centres also\u00a0demonstrates\u00a0the practicality of implementing this approach in routine care.\u00a0<\/p>\n
Toward Precision Medicine in Acute Respiratory Distress Syndrome\u00a0<\/p>\n